Blood and marrow transplantation in relapsed or refractory non-Hodgkin's lymphoma.
It was not until 1995 that a phase III randomized trial demonstrated that autologous stem cell transplants (ASCT) improve the progression-free and overall survival of patients with relapsed refractory diffuse aggressive non-Hodgkin's lymphoma. Investigators are now focusing on improving the clinical benefit of transplants. The relative contributions made by more intensive preparative regimens, purging, concomitant immunotherapy, and the timing of transplants are under study. Also, as transplant trials shift from relapsed disease to initial therapy, anticipated benefits must be balanced against both short-term and long-term toxicities.
Stiff
P J
PJ
Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois, USA.
D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D019008:Drug Resistance, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D012008:Recurrence